MCID: SML011
MIFTS: 31

Smoldering Myeloma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Smoldering Myeloma

MalaCards integrated aliases for Smoldering Myeloma:

Name: Smoldering Myeloma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9551
UMLS 73 C1531608

Summaries for Smoldering Myeloma

Disease Ontology : 12 A multiple myeloma that is a slow growing type of myeloma in which abnormal plasma cells results in too much of a single type of monoclonal antibody.

MalaCards based summary : Smoldering Myeloma is related to monoclonal gammopathy of uncertain significance and myeloma, multiple, and has symptoms including bone pain An important gene associated with Smoldering Myeloma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are Keratan sulfate/keratin metabolism and N-Glycan biosynthesis. The drugs Lenalidomide and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and nk cells.

Related Diseases for Smoldering Myeloma

Diseases related to Smoldering Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 monoclonal gammopathy of uncertain significance 10.3
2 myeloma, multiple 10.1
3 diabetes mellitus, noninsulin-dependent 9.9
4 sickle cell anemia 9.9
5 arthritis 9.9
6 diabetes mellitus 9.9
7 hepatitis 9.9
8 leukemia 9.9
9 lymphocytic leukemia 9.9
10 hepatitis c 9.9
11 progressive multifocal leukoencephalopathy 9.9
12 septic arthritis 9.9
13 amyloidosis 9.9
14 scleredema 9.9

Graphical network of the top 20 diseases related to Smoldering Myeloma:



Diseases related to Smoldering Myeloma

Symptoms & Phenotypes for Smoldering Myeloma

UMLS symptoms related to Smoldering Myeloma:


bone pain

Drugs & Therapeutics for Smoldering Myeloma

Drugs for Smoldering Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
4
Daratumumab Approved Phase 3,Phase 2 945721-28-8
5
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
6
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
7 BB 1101 Phase 3,Phase 2,Phase 1
8 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
9 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
11 Hormones Phase 3,Phase 2,Phase 1
12 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
13 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
14 Antiemetics Phase 3,Phase 2,Phase 1
15 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
16 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
17
protease inhibitors Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
20 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
21 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
22 Hormone Antagonists Phase 3,Phase 2,Phase 1
23 Autonomic Agents Phase 3,Phase 2,Phase 1
24 glucocorticoids Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Antibodies Phase 3,Phase 2,Phase 1
27 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 3,Phase 2,Phase 1
29 Alkylating Agents Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
31 Nitrogen Mustard Compounds Phase 3
32 phenylalanine Phase 3,Phase 1,Phase 2
33 alanine Phase 3
34
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
35
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
36 sodium fluoride Approved Phase 2 7681-49-4
37
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
38 Siltuximab Approved, Investigational Phase 2,Phase 1 541502-14-1
39 Ixazomib Approved, Investigational Phase 2,Phase 1 1072833-77-2
40
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
41
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
42
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
43
Promethazine Approved, Investigational Phase 2 60-87-7 4927
44
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
45
Ranitidine Approved Phase 2 66357-35-5, 66357-59-3 3001055
46
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
47
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
48
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
49
Nivolumab Approved Phase 2 946414-94-4
50
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression Completed NCT00480363 Phase 3
2 Thalidomide for Multiple Myeloma Completed NCT00038233 Phase 3 Thalidomide
3 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Recruiting NCT03301220 Phase 3 Daratumumab SC: daratumumab + rHuPH20
4 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT01169337 Phase 3 Lenalidomide
5 Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Active, not recruiting NCT00114101 Phase 3 Lenalidomide;Melphalan
6 Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Completed NCT01441973 Phase 2
7 Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma Completed NCT01222286 Phase 2 IPH2101
8 Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma Completed NCT01302886 Phase 2 BHQ880
9 Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
10 UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma Completed NCT01884688 Phase 2 ENK Cell Infusion
11 Imaging in MGUS, SMM and MM Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
12 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Completed NCT01094548 Phase 2 Single low dose cyclophosphamide;Multiple low dose cyclophosphamide
13 Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma Completed NCT00635154 Phase 2 Dexamethasone acetate
14 Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients Recruiting NCT02943473 Phase 2 Ibrutinib
15 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Recruiting NCT02916771 Phase 2 Ixazomib;Lenalidomide;Dexamethasone
16 Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Recruiting NCT03236428 Phase 2 Daratumumab
17 Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma Recruiting NCT02960555 Phase 2
18 Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant Recruiting NCT03289299 Phase 2 Carfilzomib;Lenalidomide;Daratumumab;Dexamethasone
19 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma Recruiting NCT01572480 Phase 2 Carfilzomib;Revlimid;Dexamethasone
20 Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM Recruiting NCT03673826 Phase 2 Carfilzomib;Dexamethasone;Lenalidomide
21 Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT02279394 Phase 2 Elotuzumab;Lenalidomide;Dexamethasone
22 A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma Active, not recruiting NCT01484275 Phase 2 Siltuximab;Placebo
23 Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma Active, not recruiting NCT02415413 Phase 2 carfilzomib;Lenalidomide;Dexamethasone;Melphalan
24 A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma Active, not recruiting NCT02316106 Phase 2 daratumumab;daratumumab;daratumumab
25 Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma Active, not recruiting NCT00112827 Phase 1, Phase 2 melphalan;cyclophosphamide;lenalidomide
26 A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) Not yet recruiting NCT03815279 Phase 2 Carfilzomib;Lenalidomide;Dexamethasone
27 Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Not yet recruiting NCT03792763 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA];Placebo 1.7 ml Subcutaneous Solution
28 A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma Suspended NCT02903381 Phase 2 Nivolumab;Lenalidomide;Dexamethasone
29 Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Suspended NCT02492750 Phase 1, Phase 2 Dexamethasone;Lenalidomide
30 Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients Terminated NCT00983346 Phase 2 Bortezomib
31 A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma Terminated NCT01248455 Phase 2 (Anti-KIR)
32 A Phase II Study of BI-505 in Smoldering Multiple Myeloma Terminated NCT01838369 Phase 2 BI-505
33 A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma Terminated NCT01302366 Phase 2 TBL12
34 Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma Terminated NCT01096810 Phase 2 TBL 12
35 Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Terminated NCT00942422 Phase 2
36 Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) Terminated NCT00899353 Phase 2
37 Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Terminated NCT02353572 Phase 1, Phase 2 Melphalan;Bortezomib;Dexamethasone
38 Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma Withdrawn NCT00503763 Phase 2 Simvastatin
39 MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma Withdrawn NCT01660997 Phase 2 MLN9708;Dexamethasone
40 Imaging Studies and the Development of Multiple Myeloma Withdrawn NCT01571726 Phase 2 Fluciclatide
41 Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Unknown status NCT02240537 Phase 1 Sargramostim;BB-MPI-03;Montanide
42 Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Completed NCT01718899 Phase 1
43 A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
44 Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma Completed NCT00698776 Phase 1 Lenalidomide
45 A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM Recruiting NCT02886065 Phase 1 Hiltonol;Citarinostat;Lenalidomide
46 Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study Active, not recruiting NCT02697383 Phase 1 Ixazomib (MLN9708);Dexamethasone
47 Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma Suspended NCT02784483 Phase 1 Atezolizumab (1200mg via IV infusion)
48 Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) Completed NCT01109407
49 Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma Completed NCT01955395 Not Applicable
50 S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. Completed NCT00919139

Search NIH Clinical Center for Smoldering Myeloma

Genetic Tests for Smoldering Myeloma

Anatomical Context for Smoldering Myeloma

MalaCards organs/tissues related to Smoldering Myeloma:

41
Bone, Bone Marrow, Nk Cells, T Cells

Publications for Smoldering Myeloma

Articles related to Smoldering Myeloma:

(show all 42)
# Title Authors Year
1
Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. ( 29907380 )
2018
2
The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. ( 29795240 )
2018
3
Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. ( 28540748 )
2018
4
Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma. ( 30315756 )
2018
5
Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity. ( 30377233 )
2018
6
Timing of treatment of smoldering myeloma: early treatment. ( 30425068 )
2018
7
Timing of treatment of smoldering myeloma: delay until progression. ( 30425069 )
2018
8
Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. ( 28341370 )
2017
9
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. ( 29296837 )
2017
10
Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. ( 27013181 )
2016
11
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. ( 27804161 )
2016
12
Treatment of high-risk smoldering myeloma. ( 28061988 )
2016
13
High-risk smoldering myeloma: Perspective on watchful monitoring. ( 28061989 )
2016
14
Septic Arthritis & Smoldering Myeloma. ( 25862774 )
2015
15
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. ( 26490489 )
2015
16
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. ( 24935722 )
2014
17
Spurious platelet count due to cryoglobulins in a patient with smoldering myeloma. ( 25118751 )
2014
18
Treatment of smoldering myeloma: early or delayed? ( 24461801 )
2014
19
Classifying ultra high-risk smoldering myeloma. ( 25371175 )
2014
20
Treatment for high-risk smoldering myeloma. ( 24171527 )
2013
21
Treatment for high-risk smoldering myeloma. ( 24171530 )
2013
22
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. ( 24145347 )
2013
23
Can NKT cells extinguish smoldering myeloma? ( 23329692 )
2013
24
Phagocytic plasma cells in a patient with smoldering myeloma. ( 23605438 )
2013
25
Treatment for high-risk smoldering myeloma. ( 24171528 )
2013
26
New approaches to smoldering myeloma. ( 23975678 )
2013
27
Treatment for high-risk smoldering myeloma. ( 24171529 )
2013
28
Treatment for high-risk smoldering myeloma. ( 24171526 )
2013
29
Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report. ( 22747665 )
2012
30
Increased blood viscosity and red blood cell aggregation in a patient with sickle cell anemia and smoldering myeloma. ( 22930533 )
2012
31
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. ( 21325290 )
2011
32
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. ( 20645101 )
2011
33
Monoclonal gammopathy of undetermined significance versus smoldering myeloma: is active surveillance enough? ( 21600358 )
2011
34
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. ( 21888257 )
2011
35
Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. ( 21239809 )
2010
36
Smoldering myeloma in HIV patient: a complete remission after antiretroviral therapy. ( 18221995 )
2008
37
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( 18669874 )
2008
38
Type 2 diabetes mellitus complicated with smoldering myeloma and non-alcoholic steatohepatitis. ( 16157983 )
2005
39
Burkholderia cenocepacia vaginal infection in patient with smoldering myeloma and chronic hepatitis C. ( 15550207 )
2004
40
Smoldering myeloma associated with zonisamide treatment. ( 11868602 )
2002
41
Scleredema and smoldering myeloma. ( 1569250 )
1992
42
Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. ( 2137853 )
1990

Variations for Smoldering Myeloma

Expression for Smoldering Myeloma

Search GEO for disease gene expression data for Smoldering Myeloma.

Pathways for Smoldering Myeloma

GO Terms for Smoldering Myeloma

Cellular components related to Smoldering Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi cisterna membrane GO:0032580 8.62 B4GALT1 FUT8

Biological processes related to Smoldering Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein glycosylation GO:0006486 9.16 B4GALT1 FUT8
2 protein N-linked glycosylation GO:0006487 8.96 B4GALT1 FUT8
3 oligosaccharide biosynthetic process GO:0009312 8.62 B4GALT1 FUT8

Sources for Smoldering Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....